Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection
Emergent Coronary Procedure
Primary: Occurrence of Contrast-induced Nephropathy — 1; 8 participants
Phase 3 N=301 Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
Renal Failure
Primary: Contrast-induced Nephropathy — 6.1; 6.0 percentage of contrast nephropaty
Phase 2 N=271 Sodium Chloride and Contrast Nephropathy
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
N/A N=101 Remote Ischemic Preconditioning and Contrast Induced - Acute Kidney Injury in Patients Undergoing Elective PCI
Remote Ischemic Preconditioning · Contrast Induced - Acute Kidney Injury
Primary: Number of Participants With Contrast Induced-Acute Kidney Injury — 2; 3 participants
Phase 2 N=399 N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Radiocontrast Nephropathy
Primary: Number of Participants With Contrast-induced Nephropathy — 14; 12 Participants — p=>0.5
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 4 N=57 Kidney Damage in Patients With Moderate Fall in eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL
Phase 4 N=49 Kidney Damage in Patients With Normal eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. — -14.84; -17.71; -9.98; -2.37 ng/mL
N/A N=109 Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury
Contrast-induced Acute Kidney Injury
Primary: Number of Patients With Acute Kidney Injury — 8; 16 Participants
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
N/A N=578 AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
Contrast Induced Nephropathy (CIN)
Primary: Primary Effectiveness Endpoint — 76; 75 Participants
Phase 3 N=852 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Kidney Transplantation
Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001
N/A N=513 Comparison of Contrast Agents During CT Angiography
Contrast Enhancement on Cardiac CT
Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units
Phase 2 N=92 Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Kidney Injury
Primary: Number of Participants With Acute Kidney Injury — 20; 14 participants
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Phase 2 N=527 Calcineurin Inhibitor Sparing After Kidney Transplantation
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants
Phase 4 N=100 Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Coronary Artery Disease
Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes
Phase 4 N=30 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Renal Transplant Rejection · Immunosuppression
Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05
Phase 2 N=10 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Urinary Tract Infection · Vesicoureteral Reflux
Primary: Visualization of Renal Scars Compared to Previous Imaging — 100 Percentage of previous scars visualized
N/A N=166 Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
Diabetes Mellitus · Lactic Acidosis
Primary: Incidence of Lactic Acidosis — 0; 0 participants
Phase 4 N=20 Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Kidney Transplant
Primary: Graft Survival — 13; 7 participants — p=0.849
N/A N=11 Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants
N/A N=40 Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery
Kidney Failure, Acute · Acute Kidney Insufficiency
Primary: Development of Post-operative Acute Kidney Injury — 10; 7 participants meeting primary oputcome
Phase 2 N=30 Fluid Chloride and AKI in Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Change in [TIMP2]*[IGFBP7] Biomarker — 0.015; 0.009 (ng/mL)^2/1000
Phase 3 N=5,177 Prevention of Serious Adverse Events Following Angiography
Acute Renal Failure · Kidney Disease · Coronary Artery Disease
Primary: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing…
Phase 2 N=45 Berinert (C1INH) vs Placebo for DGF/IRI
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Need for Dialysis in the First 30 Days Post-transplant — 10; 10 Participants
N/A N=134 Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
Acute Kidney Injury · Nephrotoxicity
Primary: Number of Patients With Nephrotoxic Medication Associated AKI Detected by Urinary NGAL — 3; 6; 24; 80 Participants